Just got this on a board in Sweden:
"Ceplene är godkänd av läkemedelsverket och förväntas ingå i läkemedelsförmånen våren 2011."
Meaning that the Swedish authority have approved the use of the drug and that the formal price regulation and ensurance issues will be officially solved "in spring 2011"
The source is a Meda-page for people working in health care.
Probably this is just one of several news of this kind to role in the upcoming weeks.
Congrat to Kristoffer and management!
We really appreciate your DD. But with this company and its managment, most time news means nothing until there BEEF. I recall you did some calculation back one year ago something like one treatment $xxx, one month xxx treatments equal $ xxx. Now tell us
When EPCT can make their first millione, next Qr? the Qr after next? next year? 5 years later?
As for the cash flow from Ceplene, wait for the reimbursment deals to be done in the big five in the EU.
As for the financing, you will have it in January. The point here is that this is a possibility for management to expose some of the hidden values in the CO.
Azixa - if MYRX performs a deal with a major they will have 2 or three times the share Epicept already have here. Epicept carried, Myrx not.
NP-1 - this is a challanging part. What is the upfront, not the milestones, to recieve from a market of appr 500 - 1 billion USD?
Crolibulin - Let's be ruff: Oxigene is walking out and Crinobulin is taken it's place. Value, half of Oxigenes market cap?
The diagnosis for the two other leukemias.
Some two years ago I argue on this board that it was wise not to dillute the patent. -let's see how the road map for the CO looks like after the financing is done.
If you ask me about the share price, fingers crossed, I believe we will have a return to the levels one year ago. The reasons for this is that the EU-sales will start after the reimbursment deals, new markets will be adressed by applications - and, soon, the broader pipeline in the CO will be shown to the public. Being away for a time, now I am in again.
Good luck, what ever road you choose!
Ceplene is indicated for remission maintenance therapy and prevention of relapse in adult patients with acute myeloid leukemia (AML). AML is one of four main types of leukemia. Each year about 16,000 new cases of AML are diagnosed in Europe. Most patients suffer from relapse after initial treatment. There is currently no alternative treatment, and the medical need is substantial. Ceplene is approved by the European Commission as an orphan drug, and registration in other key markets is underway. Ceplene is also being investigated for other indications such as myelodysplastic syndrome (MDS) and chronic myelogenous leukemia (CML).